How Should Technical Files for Medical Device Registration in Japan Be Organized?

Answer: To organize technical files for medical device registration in Japan, companies should first confirm the target country, product risk class, applicable regulatory pathway, and existing documentation base. They should then assess technical files, quality system, labeling and instructions for use, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid prolonged project timelines caused by unclear classification, documentation, or authorization arrangements.

For Chinese medical device companies, a more reliable approach is to first perform product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused. Target market registration typically affects technical files, authorized representative, importer cooperation, label language, quality system certification, and subsequent change maintenance. If the project is driven only by “which documents to submit,” corrections or rework often occur in model coverage, evidence chain consistency, labeling claims, and certificate control. AIMEILI recommends that companies plan this issue within a unified strategy for GHWP member states and multiple market access, using one reusable core technical file to support localization in different markets, rather than recreating documents for each country on an ad hoc basis.

This content is compiled from AIMEILI’s regulatory practice question bank, medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country’s regulatory authority and the product documentation base.

Published: 2026-07-15 18:35 | Updated: 2026-07-15 18:35

Key Takeaways

• First confirm target country, product risk class, applicable regulatory pathway, and existing documentation.
• Assess technical files, quality system, labeling, local agent, clinical evidence, and post-market maintenance.
• Conduct a documentation gap assessment before formal submission to avoid delays.
• Determine whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused.
• Plan within GHWP member states and multi-country access strategy for reusable core technical files.

Applicable Scenarios and Core Questions

Companies searching for “how to organize technical files for medical device registration in Japan” usually want to determine whether their existing documentation can support the target market submission, whether a local agent or authorized representative is needed, why timelines are extended, and which issues affect launch plans. This question often involves product classification, registration pathway, evidence chain, labeling localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for one country alone is not enough. A more valuable approach is to first develop reusable versions of core technical files, quality system certificates, performance verification, clinical evidence, and labeling, and then localize them according to each country’s regulatory requirements.

Registration Decision Logic

Companies should first confirm the product’s intended use, mechanism of action, use scenario, body contact method, duration of use, whether it is sterile, whether it is active, and whether it contains software or IVD attributes, and then determine the risk class and submission pathway. If the pathway is incorrectly determined, subsequent translation, notarization, authorization, testing, and supplementary documentation will all deviate from the correct direction.

For a target market project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in commercial contracts, they can easily affect market control later.

Documents and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system certification, technical files, performance verification reports, risk management documents, clinical evaluation or clinical evidence, labeling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documents.

The key to document quality is not quantity but consistency. Instruction claims, test report coverage of models, clinical evidence scope, risk management conclusions, label warnings, and registration application form information must support each other. Regulatory authorities focus on whether the product is safe, effective, and traceable for the intended use, not on how many documents the company has uploaded.

Common Mistakes

• The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.
• Directly translating NMPA documents and submitting them without rearranging evidence according to the target market pathway.
• Having too many model specifications but insufficient coverage by test reports, clinical evidence, or labeling.
• Selecting a local agent only based on sales cooperation without clarifying regulatory responsibilities, certificate control, and post-market maintenance responsibilities.
• Inconsistencies among labels, instructions, promotional materials, and registration claims, leading to corrections or post-market compliance risks.
• Failing to plan for multi-country document reuse in advance, resulting in repeated preparation for each country and increased cost and timeline.

Company Preparation Checklist

Before starting the project, companies should use an internal checklist to confirm the documentation base to avoid discovering key evidence gaps after submission.

• Organize the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English instructions for use.
• Confirm the responsibilities, fees, certificate control, and exit mechanism of the local agent or authorized representative.
• Establish a target country gap assessment table specifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI’s View

AIMEILI recommends that companies not view target market registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, first establishing a clear core technical file and evidence matrix and then converting it according to national requirements is usually faster, more stable, and more conducive to subsequent changes and renewals than supplementing documents on a country-by-country basis.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the document evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documents appear numerous, the project may still experience repeated issues during corrections, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic documents be used directly for target market registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, labeling adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

The local agent usually participates in registration communication, changes, renewals, and post-market event handling. Unclear responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger to manage the product list, model specifications, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission dates in one table. This helps identify document gaps in a timely manner and enables management to judge whether the project will affect the launch plan.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. In particular, labeling, clinical evaluation, risk management, performance verification, and quality system certificates must maintain consistent versions.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a document gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing, and correction status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documents are not isolated certificates. Regulatory authorities usually check whether the manufacturer name, manufacturing address, product scope, certificate validity, applicable standards, and technical files are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model specifications, instruction version, and test reports are inconsistent, even if the company has prepared a large number of documents, it may be asked for supplementary explanations.

Companies should establish an evidence consistency checklist before submission, mapping product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labeling version, and quality system certificate item by item. This action may seem basic, but it can significantly reduce the probability of corrections, especially for projects submitted simultaneously in multiple GHWP member states or for multiple product series.

Localization and Agent Responsibilities

Target market registration projects usually involve local agent, authorized representative, importer, or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions, and authorization documents cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance. If a manufacturing address change, model expansion, instruction update, or agent replacement occurs later, the certificate may become disconnected from market sales.

AIMEILI recommends that companies incorporate this issue into annual international registration plan management: first clarify target market priorities, then establish a reusable document package and country gap list, and finally arrange submission, correction, post-market maintenance, and renewal milestones. The value of this is not only improving registration efficiency in a single country, but more importantly enabling companies to develop a replicable overseas compliance capability and reduce the cost of starting from scratch every time they enter a new market.

Further Reading

Previous: How to Determine Product Classification for Medical Device Registration in Japan?

Next: How to Localize Labels and Instructions for Medical Device Registration in Japan?

Recommended Reading:

• How to Choose a Local Agent for Medical Device Registration in Brazil?
• How Are Authorized Representative Responsibilities Divided for Medical Device Registration in Brazil?
• Why Is the Registration Timeline Extended for Medical Device Registration in Brazil?
• What Are Common Reasons for Document Corrections in Medical Device Registration in Brazil?
• How to Conduct Post-Market Surveillance for Medical Device Registration in Brazil?
• When Must Registration Changes Be Reported for Medical Device Registration in Brazil?

Return to FAQ Center | News | Contact AIMEILI

Content Review and Scope of Application

Author: AIMEILI Regulatory Editorial Team

Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory information; industry media and project experience are used only as auxiliary judgment.

Scope of Application: This article is for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country’s regulatory authority, test conclusions, or legal opinions.